Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF	CHANGES IN	I BENEFICIAL	OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ARMEN GARO H				2. Issuer Name and Ticker or Trading Symbol MiNK Therapeutics, Inc. [ INKT ]									ationship k all app Direc	,	ng Per	rson(s) to Is			
(Last)	(Fi	rst) (f	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/02/2023									Office	er (give title v)		Other (s	specify	
149 FIFTH AVENUE, SUITE 500				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street)											X Form filed by One Reporting Person								
NEW YO	ORK N'	Y 1	0010												Perso	m filed by More than One Reporting son			
(City)	(St	ate) (Ž	Zip)		Rul	le 10	)b5-	1(c)	Trar	nsac	tion Indi	icatio	on						
					Check this box to indicate that a transaction was made pursuant t satisfy the affirmative defense conditions of Rule 10b5-1(c). See I														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day.			Execution Dat		,	Transaction Dispos			es Acquired (A) o Of (D) (Instr. 3, 4		l and 5) Secu Bene Owne		rities For efficially (D ed Following (I)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) o (D)	r Price	,	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 05/02/20				023			P		100,000	A	\$0.9	9485	1,978,010			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	version   Date   Execution Date,   Tild any   C   C   C   C   C   C   C   C   C			Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares						

**Explanation of Responses:** 

By: /s/ Christine Klaskin, 05/04/2023 Attorney-in-Fact for Garo H.

Armen

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).